Key facts
- European Commission approved Amgen's IMDYLLTRA for extensive-stage small cell lung cancer.
- Approval is based on Phase III DeLLphi-304 trial results.
- IMDYLLTRA reduced the risk of death by 40% compared to chemotherapy.
- It offers a new treatment option for patients with disease progression.
The European Commission has granted approval for Amgen's IMDYLLTRA (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. This decision follows the positive results from the Phase III DeLLphi-304 clinical trial. The trial demonstrated that IMDYLLTRA significantly reduced the risk of death by 40% compared to the current standard of care, chemotherapy. This approval marks a significant advancement, providing a new therapeutic option for patients with SCLC who have experienced disease progression.